TCGA-BH-A0EE-01A-11R-A034-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 31
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.680
- E2F_TARGETS+0.490
- INTERFERON_GAMMA_RESPONSE+0.490
- CHOLESTEROL_HOMEOSTASIS+0.410
- MYC_TARGETS_V1+0.410
- GLYCOLYSIS+0.390
- G2M_CHECKPOINT+0.380
- OXIDATIVE_PHOSPHORYLATION+0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340
- FATTY_ACID_METABOLISM+0.330
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- ANGIOGENESIS-0.460
- UV_RESPONSE_DN-0.350
- MYOGENESIS-0.340
- APICAL_JUNCTION-0.290
- ESTROGEN_RESPONSE_EARLY-0.290
- MITOTIC_SPINDLE-0.280
- TGF_BETA_SIGNALING-0.270
- WNT_BETA_CATENIN_SIGNALING-0.250
- COAGULATION-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20070130.TNBC | — | C | 0.874 |
| 2 | TCGA-AO-A0J2-01A-11R-A034-07 | — | C | 0.873 |
| 3 | e0464181-da72-4a14-9039-a396843c39f2 | — | — | 0.864 |
| 4 | 992ce1bc-46a2-4f57-ac7a-c6368c69c67c | — | — | 0.860 |
| 5 | ERR2278852 | — | — | 0.854 |
| 6 | TCGA-80-5611-01A-01R-1628-07 | — | cohortA4 | 0.851 |
| 7 | TCGA-GM-A3XL-01A-11R-A22U-07 | — | E | 0.850 |
| 8 | TCGA-66-2794-01A-01R-1201-07 | — | cohortSQ2 | 0.846 |
| 9 | 81b828aa-cb06-4790-ba3e-efaa39f4eeef | — | — | 0.845 |
| 10 | GSM5359417 | — | — | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.680 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.410 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.390 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |